Poxel SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Poxel SA - overview
Established
2009
Location
Lyon, -, France
Primary Industry
Biotechnology
About
Poxel SA is a biopharmaceutical company focused on developing innovative therapies for chronic diseases with metabolic components, specifically targeting conditions such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel SA operates out of Lyon, France, focusing on the development of treatments for chronic metabolic diseases. The company has executed a total of 9 deals, with the latest funding round being a Private Placement/Follow on in November 2024, raising EUR 17. 690 mn.
The CEO is Thomas Kuhn, and the company was established under the leadership of founder Sophie Bozec. Poxel SA specializes in the development of innovative biopharmaceutical products targeting chronic diseases with metabolic components. The company's primary offerings include PXL065, a deuterium-stabilized R-pioglitazone designed for non-alcoholic steatohepatitis (NASH); PXL770, an adenosine monophosphate-activated protein kinase (AMPK) activator aimed at rare metabolic diseases; and TWYMEEG® (Imeglimin), approved in 2021 for the treatment of type 2 diabetes in Japan. Poxel's client base includes healthcare providers and pharmaceutical partners, with a significant collaboration with Sumitomo Pharma for the commercialization of Imeglimin in Japan, targeting regions with high metabolic disorder prevalence.
In 2022, Poxel SA reported a revenue of EUR 710,260. 5 and an EBITDA of EUR -22,482,799. 4. The company generates revenue primarily through partnerships and sales of its pharmaceutical products, including royalties and sales-based payments from TWYMEEG®, marketed by Sumitomo Pharma in Japan.
In November 2024, OrbiMed Advisors agreed to provide USD 50 million in non-dilutive financing to Poxel SA, which will support future royalties and sales-based payments from TWYMEEG® sales by Sumitomo Pharma in Japan. The company is focused on expanding its product line and entering new markets as its therapies progress through clinical trials, particularly in regions with significant unmet needs for metabolic disease treatments.
Current Investors
Andera Partners, Omnes Capital, Amundi
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.poxelpharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Poxel SA - timeline of key events
Poxel SA - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 59,650 | 70,265 | 5,290,148 | 74,605,000 | 26,557,000 | - | - | - |
| % Revenue Growth (YoY) | - | 17.8% | 7428.9% | 1310.3% | (64.4%) | - | - | - |
| EBITDA (USD) | (11,697,977) | (24,250,309) | (21,864,279) | 12,600,000 | (24,247,000) | - | - | - |
| Operating Income (USD) | (11,720,952) | (24,282,320) | (21,902,177) | 12,538,000 | (24,671,000) | - | - | - |
| Operating Margin | (19649.5%) | (34558.2%) | (414.0%) | 16.8% | (92.9%) | - | - | - |
| % EBITDA Margin | (19611.0%) | (34512.6%) | (413.3%) | 16.9% | (91.3%) | - | - | - |
| NET Income (USD) | (12,241,013) | (24,482,934) | (22,298,111) | 13,525,000 | (25,743,000) | - | - | - |
| % Net Margin | (20521.4%) | (34843.7%) | (421.5%) | 18.1% | (96.9%) | - | - | - |
Poxel SA - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Poxel SA | - | ||||||||
| Private Debt | Completed | Poxel SA | - |
Displaying 1 - 2 of 2
Poxel SA - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.